Evidence map›Paper›PMID 31750841›Full record

ArticleJMIR mHealth and uHealth2019

Assessment of a Mobile App by Adolescents and Young Adults With Cystic Fibrosis: Pilot Evaluation.

Isa Rudolf, Katharina Pieper, Helga Nolte, Sibylle Junge, Christian Dopfer, Annette Sauer-Heilborn, Felix C Ringshausen, Burkhard Tümmler, Ute von Jan, Urs-Vito Albrecht and 3 more

Open access · goldAbstract read
In one paragraph

Article in JMIR mHealth and uHealth, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Telemedicine in cystic fibrosis.Journal of clinical & translational endocrinology · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Phenylketonuria.Nature reviews. Disease primers · 2021
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Isa Rudolf *Pediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-9458-702X
Katharina Pieper *Pediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-8626-161X
Helga NolteHaus Schutzengel, Mukoviszidose eV, Hannover, Germany.ORCID 0000-0002-6558-003X
Sibylle JungePediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-8850-6177
Christian DopferPediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-8932-513X
Annette Sauer-HeilbornDepartment of Respiratory Medicine, Hannover Medical University, Hannover, Germany.ORCID 0000-0001-6200-0880
Felix C RingshausenBiomedical Research in End-Stage and Obstructive Lung Disease Hannover, German Centre for Lung Research, Hannover Medical University, Hannover, Germany.ORCID 0000-0001-9084-4968
Burkhard TümmlerPediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-2566-8758
Ute von JanPeter L Reichertz Institute for Medical Informatics, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-9225-593X
Urs-Vito AlbrechtPeter L Reichertz Institute for Medical Informatics, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-8989-6696
Jan FugeBiomedical Research in End-Stage and Obstructive Lung Disease Hannover, German Centre for Lung Research, Hannover Medical University, Hannover, Germany.ORCID 0000-0003-2926-3608
Gesine HansenPediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-5185-9454
Anna-Maria DittrichPediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-9582-1025
Medizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystic fibrosis (CF) continues to be the most common life-limiting chronic pulmonary disease in adolescents and young adults. Treatment of CF demands a high treatment time investment to slow the progression of lung function decline, the most important contributor to morbidity and mortality. Adherence is challenging in CF due to the high treatment burden and the lack of immediate health consequences in case of nonadherence. Lung function decline is particularly pronounced in the transition phase between 12 and 24 years of age. The improvement of self-management and self-responsibility and independence from parents and desire for normalcy are conflicting aspects for many adolescents with CF, which influence adherence to the time-consuming pulmonary therapy. Mobile health (mHealth) care apps could help to support self-management and independence and thereby reconcile seemingly conflicting goals to improve adherence, quality of life, and ultimately CF life expectancy.

objectiveThis study aimed to (1) assess user behavior and satisfaction among adolescents and young adults with CF over an observation period of three months using an mHealth app; (2) identify areas of improvement for this mHealth app; and (3) compare overall and disease-specific satisfaction, lung function, and anthropometry before and after using the mHealth app.

methodsA total of 27 adolescents and young adults with CF (age range 12-24 years, mean age 16 years, SD 3 years; 14 females, 11 males) used a free mHealth app for three months of whom 25 provided questionnaire data for analysis at the end of the study. Data collection was carried out using questionnaires on usage characteristics and life satisfaction, and standardized assessment of lung function and anthropometry.

resultsThe use of the reminder function for medication declined from 70% (15/21) of the participants at week 4 to 65% (13/20) at week 8 of the observation period. At the end of the study, only 17% (4/23) of the participants wanted to continue using the app. Nevertheless, 56% (14/25) of participants saw the mobile app as a support for everyday life. Potential improvements targeting hedonistic qualities were identified to improve mHealth app adherence. Comparisons of satisfaction with different life aspects hinted at improvements or stabilization for the subitem respiration and the subitem lack of handicap by CF, suggesting that app use might stabilize certain CF-specific aspects of the weighted satisfaction with life. Lung function and anthropometry were not affected consistently.

conclusionsMost of the patients did not want to continue using the app after the study period. Only a few CF-specific aspects of weighted life satisfaction were possibly stabilized by the mHealth app; clinical parameters were not affected. Adaptation of the functions to adolescent-specific needs could improve the long-term use and thus positively affect the disease course.

Indexed as

AdolescentChildCystic FibrosisFemaleHumansMaleMobile ApplicationsPilot ProjectsSelf-ManagementSurveys and QuestionnairesYoung Adultadolescencecystic fibrosismHealthmobile phonemobile phone appself-management

Identifiers

PMID31750841
PMCPMC6895868
OpenAlexW2963700965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.